Legend Biotech Presents CARVYKTI Data at ASCO and EHA
Ticker: LEGN · Form: 6-K · Filed: Jun 3, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial-data, oncology, press-release
TL;DR
Legend Biotech shows CARVYKTI works for tough multiple myeloma cases post-ASCT.
AI Summary
Legend Biotech Corporation announced on June 3, 2024, new data from its Phase 2 CARTITUDE-2 Cohort D study. The study focused on multiple myeloma patients who had less than a complete response after front-line autologous stem cell transplant (ASCT). Results indicated that these patients achieved deep and durable responses after a single infusion of CARVYKTI®.
Why It Matters
This data highlights the potential of CARVYKTI® in a specific patient subgroup of multiple myeloma, potentially expanding its therapeutic use and impact.
Risk Assessment
Risk Level: low — The filing is an informational press release and does not contain significant financial or operational changes that would inherently increase risk.
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant
- CARVYKTI® (product) — Drug being studied
- June 3, 2024 (date) — Date of press release
- CARTITUDE-2 Cohort D (study) — Clinical trial name
- ASCO (conference) — Medical conference where data was presented
- EHA (conference) — Medical conference where data was presented
FAQ
What specific patient subgroup was the focus of the CARTITUDE-2 Cohort D study?
The study focused on multiple myeloma patients who had less than a complete response (CR) after front-line autologous stem cell transplant (ASCT).
What was the primary outcome reported for this patient subgroup?
Patients experienced deep and durable responses following a single infusion of CARVYKTI®.
When did Legend Biotech issue the press release announcing these results?
The press release was issued on June 3, 2024.
At which medical conferences were these results presented?
The results were presented at ASCO and EHA.
What is the filing form type and date?
The filing is a Form 6-K, filed as of June 3, 2024.
Filing Stats: 310 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2024-06-03 16:05:06
Filing Documents
- f6k_060324.htm (6-K) — 10KB
- exh_991.htm (EX-99.1) — 58KB
- logo.jpg (GRAPHIC) — 6KB
- 0001171843-24-003239.txt ( ) — 77KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: June 3, 2024 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer